Quintiles

Quintiles names Tom Pike CEO

Monday, April 23, 2012 10:01 AM

Quintiles, a global biopharmaceutical services company, has appointed Tom Pike as CEO effective April 30 as part of the company’s long-term succession planning. 

More... »


Quintiles named best CRO in vaccine excellence awards

Friday, April 13, 2012 02:01 PM

Quintiles, a global biopharmaceutical services company, has been named “Best Clinical Research Organization” (CRO) in the Vaccine Industry Excellence (ViE) Awards 2012, which recognizes and celebrates the leaders, innovators and pioneers in the vaccines industry.

More... »


Quintiles to incorporate Archimedes’ healthcare simulator

Friday, March 30, 2012 02:19 PM

Quintiles and Archimedes, a healthcare modeling organization based in San Francisco, Calif., have formed an agreement to co-promote clinical and commercial solutions for biopharmaceutical companies to help reduce the time and expense associated with developing and marketing novel therapies.

More... »

Delcath selects Quintiles to support EU launch of Chemosat

Wednesday, March 14, 2012 04:47 PM

Delcath Systems, an ongology-focused pharmaceutical company, has selected Quintiles to provide a specialized team of Medical Science Liaisons (MSLs) to support the launch of the Hepatic Chemosat Delivery System for the treatment of cancers in the liver in France, Germany, Italy, Netherlands, Spain, Ireland and the U.K. 

More... »

Quintiles and RCV Biofund to expand clinical development capabilities in Russia

Monday, February 27, 2012 09:56 AM

Quintiles and Russian Venture Company (RVC) Biofund, a Russian-based investment firm, have joined to support expansion of clinical development services within the Russian Federation, the world's ninth most populous country.

More... »

Quintiles launches strategic drug development and consulting services in Asia

Tuesday, February 14, 2012 11:52 AM

To help biopharmaceutical companies navigate the complexities of the Asia market, Quintiles has launched two services—Strategic Drug Development and Consulting at Quintiles—to bolster the probability of success in developing and commercializing new medications in the region.

More... »

Quintiles expands commercial services in Middle East and North Africa

Tuesday, February 14, 2012 11:42 AM

Quintiles is extending its global footprint to provide commercial services in the Middle East and North Africa (MENA) region through an agreement with Dayarn Pharma, a United Arab Emirates (UAE)-based company that specializes in biopharmaceutical sales, marketing and regulatory efforts needed to maximize brands in the Arab Gulf region.

More... »

Premier Research names Sean Russell marketing VP

Monday, February 13, 2012 03:53 PM

Premier Research Group has appointed Sean Russell vice president, marketing.

More... »

Quintiles launches innovative Center of Excellence in China

Wednesday, January 18, 2012 04:09 PM

Quintiles is opening a business process outsourcing (BPO) and project management center of excellence in Dalian, China, a major city with a multilingual workforce and location ideally suited to serve the Japanese, Chinese and South Korean biopharmaceutical markets.

More... »

Susan Stansfield named executive VP, clinical development at Premier Research

Friday, January 13, 2012 12:03 PM

Premier Research Group has named Susan C. Stansfield, Ph.D., its new executive vice president of clinical development.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs